Effects of oral contraceptives on lipoprotein lipids: a prospective study.

One hundred sixty-nine healthy women, aged 17 to 29 years, nonsmokers or light smokers (fewer than ten cigarettes per day), were assigned randomly to take one of five oral contraceptives: 1) 100 micrograms mestranol plus 0.5 mg ethynodiol diacetate (100 M + 0.5 ED); 2) 100 micrograms mestranol plus 1.

Oral contraceptive estrogen and plasma lipid levels.

Blood samples were obtained from 20 women, aged 18 to 30 years, before and during the use of selected oral contraceptives. The contraceptive preparation containing 100 microgram mestranol induced increases in triglycerides, esterified cholesterol, free cholesterol, and phospholipids. Ethinyl estradiol with norgestrol, on the other hand, tended to decrease the lipid levels, while preparations containing only 50 microgram mestranol produced no significant change in the levels of the four substances.

Plasminogen activator levels in plasma and urine during exercise and oral contraceptive use.

The effect of Demulen (ethinyl estradiol 0.05 mg and ethynodiol diacetate 1 mg) and exercise on the level of plasminogen activators was studied in 25 women (12 controls and 13 contraceptive users). Plasma plasminogen activator level was increased by the use of the oral contraceptive and further increased by exercise.

Hemostatic changes induced by exercise during oral contraceptive use.

Exercise-induced changes in hemostatic measurements were studied in 25 women. Twelve of the subjects were not using oral contraceptives and the remainder were using Demulen (ethynodiol diacetate (1 mg) and ethinyl estradiol (0.05 mg)).

The effect of oral contraceptive estrogen on blood coagulation and fibrinolysis.

The changes of fibrinogen, antithrombin activity, spontaneous fibrinolytic activity, plasminogen and fibrinogen degradation products were studied in women, aged 18 to 30 years, who were using oral contraceptive preparations. Blood samples were obtained before use, as well as during the first month and again after several months of use. The results were divided into three groups based on the antiovulatory activity of the estrogen component of the oral contraceptive, ie.